- Trials with a EudraCT protocol (492)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
492 result(s) found for: Cervical Cancer AND Cancer.
Displaying page 1 of 25.
EudraCT Number: 2008-007763-16 | Sponsor Protocol Number: 1.0 | Start Date*: 2009-05-06 | ||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie | ||||||||||||||||||
Full Title: Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
Medical condition: Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017054-12 | Sponsor Protocol Number: 1775-008 | Start Date*: 2010-05-20 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Two Part, Phase I-IIa Study Evaluating MK-1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer | |||||||||||||
Medical condition: Patients with advanced, metastatic, and recurrent carcinoma of the uterine cervix | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000269-42 | Sponsor Protocol Number: 1-23-456 | Start Date*: 2022-06-08 | |||||||||||
Sponsor Name:Randers Regional Hospital, Department of Gynecology and Obstetrics | |||||||||||||
Full Title: Improving diagnostics in cervical dysplasia | |||||||||||||
Medical condition: Abnormal cervical cells | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001169-34 | Sponsor Protocol Number: HPV_Elimination | Start Date*: 2021-03-24 | ||||||||||||||||
Sponsor Name:Region Stockholm [...] | ||||||||||||||||||
Full Title: Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden | ||||||||||||||||||
Medical condition: HPV infection and related diseases, such as cervical intraepithelial neoplasia grade 2 and 3 and cervical cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004844-20 | Sponsor Protocol Number: ADXS001-02 | Start Date*: 2017-05-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Advaxis, Inc | ||||||||||||||||||||||||||||||||||||||
Full Title: Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence) | ||||||||||||||||||||||||||||||||||||||
Medical condition: High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy and radiation therapy. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003396-52 | Sponsor Protocol Number: EORTC55994 | Start Date*: 2009-09-24 | |||||||||||||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||||||||||||
Full Title: Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer. | |||||||||||||||||||||||
Medical condition: Cervical carcinoma (including squamous cell carcinoma, adenosquamous cell or adenocarcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003507-19 | Sponsor Protocol Number: HOPE9 | Start Date*: 2020-09-10 | |||||||||||||||||||||
Sponsor Name:AZIENDA USL TOSCANA NORD OVEST | |||||||||||||||||||||||
Full Title: “Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy of pre-surgical HPV 9-valent vaccination in women treated with electrosurgical excision with diat... | |||||||||||||||||||||||
Medical condition: Prevention of recurrence after a first episode of high-grade cervical intraepithelial neoplasia (CIN2 +) up to initially invasive cervical cancer (FIGO IA1) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003413-25 | Sponsor Protocol Number: GCT1015-04 | Start Date*: 2018-03-07 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A single arm, multicenter, international trial of tisotumab vedotin (HuMax®-TF-ADC) in previously treated, recurrent or metastatic cervical cancer | |||||||||||||
Medical condition: recurrent or metastatic cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006309-17 | Sponsor Protocol Number: A7-14. | Start Date*: 2009-11-19 | |||||||||||
Sponsor Name:KONSTANTINAS POVILAS VALUCKAS, INSTITUTE OF ONCOLOGY OF VILNIUS UNIVERSITY | |||||||||||||
Full Title: Significance of prognostic and predictive factors for the efficacy and safety of neoadjuvant chemotherapy in combination with chemoradiation administered in patients with locally advanced cervical ... | |||||||||||||
Medical condition: Locally advanced IIB-IIIB stages cervical cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003177-42 | Sponsor Protocol Number: COHEAHR-WP4 | Start Date*: 2014-10-10 | ||||||||||||||||
Sponsor Name:Catalan Institute of Oncology | ||||||||||||||||||
Full Title: Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 30 to 45 years | ||||||||||||||||||
Medical condition: Cervical cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) ES (Completed) BE (Completed) FI (Completed) SI (Completed) NL (Completed) SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006946-24 | Sponsor Protocol Number: NV25025 | Start Date*: 2009-12-10 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high... | ||||||||||||||||||
Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2010-019657-18 | Sponsor Protocol Number: 1.0 | Start Date*: 2010-06-04 | ||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie | ||||||||||||||||||
Full Title: Topical Imiquimod in Treating Patients with Persistent HPV-Infection after Surgical or Radiation Treatment of Cervical Cancer | ||||||||||||||||||
Medical condition: Patients with positive high risk HPV-test 6 months after surgical or radiation treatment for cervical cancer are eligible for this trial. After signing informed consent patients are randomized to H... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002271-34 | Sponsor Protocol Number: GINECO-CE108b | Start Date*: 2020-02-13 | ||||||||||||||||||||||||||
Sponsor Name:ARCAGY-GINECO | ||||||||||||||||||||||||||||
Full Title: A multicenter, pilot study evaluating immune impact and safety of nivolumab in combination with ipilimumab (immune combination) before initial RT-CT treatment for cervix cancer. COLIBRI Study | ||||||||||||||||||||||||||||
Medical condition: Patients with cervical squamous cell carcinoma stage IB3 to IVa | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003072-12 | Sponsor Protocol Number: 01082018 | Start Date*: 2019-02-05 | |||||||||||||||||||||||||||||||
Sponsor Name:rigshospitalet | |||||||||||||||||||||||||||||||||
Full Title: Radiation Therapy Planning by Multi-parametric PET/MRI Imaging in patients with cervical cancer | |||||||||||||||||||||||||||||||||
Medical condition: cervical cancer | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023271-26 | Sponsor Protocol Number: MI-CI-C02 | Start Date*: 2011-02-01 | |||||||||||
Sponsor Name:Mithra Pharmaceuticals SA | |||||||||||||
Full Title: A randomized, double-blind, multi-centre, placebo controlled phase II clinical study to evaluate the efficacy, tolerance and safety of an aqueous gel containing 2% (w/w) of cidofovir, directly appl... | |||||||||||||
Medical condition: High Grade of Cervical Intraepithelial Neoplasia (CIN). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005436-33 | Sponsor Protocol Number: CITUR08-HM/SONOCOL | Start Date*: 2009-01-21 | ||||||||||||||||
Sponsor Name:CHRU de TOURS | ||||||||||||||||||
Full Title: Apport de l’échographie doppler avec injection de contraste pour la prise en charge des cancers du col de l’utérus de stade IB et II traités par radiochimiothérapie concomitante | ||||||||||||||||||
Medical condition: Cancer du col de l'utérus épidermoïde ou adénocarcinome, de stade IB et IIA > à 4 cm ou IIB proximal | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005626-24 | Sponsor Protocol Number: 1247 | Start Date*: 2006-12-07 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: PHASE II STUDY ON PEMETREXED IN ADVANCED AND/OR RECURRENT CERVICAL CANCER | |||||||||||||
Medical condition: advanced or metastatic cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005578-12 | Sponsor Protocol Number: 08-PIR-06 | Start Date*: 2009-03-02 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanc... | |||||||||||||
Medical condition: Patients with Metastatic or Locally Advanced Cervical Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000318-12 | Sponsor Protocol Number: MITOCERV3 | Start Date*: 2020-02-20 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer | |||||||||||||
Medical condition: Locally advanced cervical cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011682-91 | Sponsor Protocol Number: 64Cu-ATSM-UTERO-01/2009 | Start Date*: 2009-09-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Role of 64Cu-ATSM PET/CT for the localization of hypoxic areas in uterine cervical cancer | |||||||||||||
Medical condition: Patients affected by uterine cervical cancer (sensitivity for localizing area of hypoxia within tumoral masses will be evaluated ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
